Company / Operating Margin
SUTRO BIOPHARMA, INC. Operating Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-384.3%
FY2025
5-year range
-384.3% / -129.8%
FY2021-FY2025
Trend
-102.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -159.2% to -384.3% over the past 2 years.
Based on SEC 10-K filings.
-384.3% in FY2025 with a 5-year CAGR of -287.4%.
Declined from -159.2% to -384.3% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -218.0pp
- 5-Year Change
- -287.4pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin decreased 102.0% year-over-year.
- Peak operating margin was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -384.3% | -102.0% |
| FY2024 | -190.3% | -19.5% |
| FY2023 | -159.2% | +4.3% |
| FY2022 | -166.3% | -28.1% |
| FY2021 | -129.8% | -34.0% |
| FY2020 | -96.9% | -160.1% |
| FY2019 | -37.3% | -1733.8% |
| FY2018 | 2.3% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026